Publications by authors named "G Wensing"

Claim this Profile
H
How to Interpret an Investigator's Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion Forum.
Jens Rengelshausen, Kerstin Breithaupt-Groegler, Frank Donath, Katharina Erb-Zohar, Tim Hardman, Georg Wensing

Ther Innov Regul Sci· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of healthy subjects in first-in-human multiple-dose studies: A pooled analysis.
David Jung, Inka Valeska Braun, Georg Wensing

Int J Clin Pharmacol Ther· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How safe are our studies? Analysis of adverse events in Bayer First-in-Human trials from 2006 to 2016
.
David Jung, Michael-Friedrich Boettcher, Georg Wensing

Int J Clin Pharmacol Ther· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia.
M Böttcher, S Lentini, E R Arens, A Kaiser, D van der Mey, G Wensing

Br J Clin Pharmacol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Who is a 'healthy subject'?-consensus results on pivotal eligibility criteria for clinical trials.
Kerstin Breithaupt-Groegler, Christoph Coch, Martin Coenen, Frank Donath, Katharina Erb-Zohar, Georg Wensing

Eur J Clin Pharmacol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis